TEVA vs ZTS
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
TEVA · Teva Pharmaceutical Industries$42.61 ▲ 1.99%
ZTS · Zoetis$79.40 ▼ 3.30%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- TEVA +75.6%
- ZTS -32.7%
Head to head
| Metric | TEVA | ZTS |
|---|---|---|
| Price | $42.61 | $79.40 |
| Change today | ▲ 1.99% | ▼ 3.30% |
| Market cap | $49.72B | $32.26B |
| Return, 3 months | +17.9% | +6.1% |
| Return, year to date | +36.5% | -35.9% |
| Return, 1 year | +77.8% | -32.9% |
| P/E (TTM) | 99.1 | 13.4 |
| P/B | 6.2 | 9.8 |
| P/E percentile vs own 5y | 100th | 10th |
| Dividend yield | – | 2.63% |
| Revenue growth (YoY, latest qtr) | -0.8% | -0.2% |
| Net profit growth (YoY) | -303.2% | -4.8% |
| Gross margin | 52.5% | 71.7% |
| Operating margin | 18.7% | 37.9% |
| Net margin | 4.1% | 27.7% |
| Return on equity | 9.7% | 64.9% |
| Analyst target vs. price | +16.9% | +13.4% |
| Analyst buy share | 100% | 36% |
| RSI (14) | 63 | 51 |
| 30-day volatility | 26.7% | 43.9% |
| Max drawdown, 1 year | -21.8% | -52.3% |
| Trend read | Strong uptrend | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- TEVA is the largest of the group by market value.
- TEVA has returned the most over the past year.
- ZTS carries the lowest trailing P/E.
- ZTS is growing revenue fastest.
- ZTS keeps the most profit per dollar of sales.
- TEVA has been the calmest stock over the last 30 days.